Reviewer's report

Title: Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer

Version: 1 Date: 31 March 2010

Reviewer: Marc L. Citron

Reviewer's report:

1. Is the question posed by the authors well defined? yes
2. Are the methods appropriate and well described? yes
3. Are the data sound? yes
4. Does the manuscript adhere to the relevant standards for reporting and data deposition? yes
5. Are the discussion and conclusions well balanced and adequately supported by the data? yes
6. Are limitations of the work clearly stated? yes
7. Do the authors clearly acknowledge any work upon which they are building, both published and unpublished? yes
8. Do the title and abstract accurately convey what has been found? yes
9. Is the writing acceptable? yes

A product of respected researchers, this well constructed study establishes the feasibility of capecitabine after sequential dose-dense epirubicin and paclitaxel. I recommend acceptance without revision.